leadf
logo-loader
viewVolitionRx

VolitionRx welcomes Veterinary Centers of American executive Tom Butera to its board of directors

Butera was previously Chief Medical Officer of Pet Partners LLC, a chain of veterinary clinics that he founded

Dog at the vet
The Nu.Q Vet Cancer Screening Test is a low-cost, easy-to-use screening test that identifies circulating nucleosomes, which are early markers of cancer, from a simple blood sample

VolitionRx Limited (NYSEAMERICAN:VNRX), an epigenetics company developing diagnostic blood tests for humans and animals, announced Thursday that veterinarian Tom Butera has joined the company’s board of directors, effective December 1.  

Butera was previously Chief Medical Officer of Pet Partners LLC, a chain of veterinary clinics that he founded, which was acquired by Mars Veterinary Health (MVH) in 2016. He currently serves as business development director at Veterinary Centers of America (VCA), which is also part of MVH.  

He received his Bachelor of Arts degree from Fairfield University and his Doctorate of Veterinary Medicine from the University of Missouri Veterinary School.

READ: VolitionRx launches reliable Nu.Q Vet Cancer Screening Test in the US

"We are pleased to welcome Tom to the Volition board of directors," Chairman Martin Faulkes said in a statement. "Tom is a proven entrepreneur, innovator and value-based leader in the healthcare field, and we are confident he will bring a deep scientific understanding, as well as valuable strategic, operational and management experience at life science and veterinary companies to our board. This is a particularly timely appointment, given the launch of our Nu.Q Vet Cancer Screening Test earlier this week."

The Nu.Q Vet Cancer Screening Test is a low-cost, easy-to-use screening test that identifies circulating nucleosomes, which are early markers of cancer, from a simple blood sample. It is a less invasive diagnostic process.

"I am excited to join the board of a purpose-driven company that leads through innovation to enhance the health and well-being of people and pets," Butera said. "I look forward to working closely with my fellow directors and the Volition leadership team to deliver on our purpose while creating long-term value for our stakeholders."

Butera was also appointed to the company's audit, compensation and nominations and governance committees, the company said.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: VolitionRx

Price: 4.08 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $215.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

on 11/13/2020

2 min read